22 Sep 2015 10:00
ABZENA PLC
("Abzena", the "Company" or the "Group")
Result of AGM
Cambridge, UK - 22 September 2015: Abzena plc (AIM: ABZA), the life sciences company providing services and technologies to enable better biopharmaceutical products, announces that at its Annual General Meeting held yesterday at 10:30am at Babraham Research Campus, Cambridge CB22 3AT, all resolutions were duly passed on a show of hands.
Details of the proxy votes received in advance of the meeting in relation to each of the resolutions (which are more particularly described in the Notice of Annual General Meeting) are as follows:
Resolution Number | For | Percentage of proxy votes received in favour | Against | Percentage of proxy votes received against | Abstaining | Percentage of proxy votes received abstaining | Total Votes |
Resolution 1 | 70,164,234 | 99.98% | - | - | 14,191 | 0.02% | 70,178,425 |
Resolution 2 | 70,164,234 | 99.98% | - | - | 14,191 | 0.02% | 70,178,425 |
Resolution 3 | 70,164,234 | 99.98% | - | - | 14,191 | 0.02% | 70,178,425 |
Resolution 4 | 70,164,234 | 99.98% | - | - | 14,191 | 0.02% | 70,178,425 |
Resolution 5 | 70,164,234 | 99.98% | - | - | 14,191 | 0.02% | 70,178,425 |
Resolution 6 | 70,164,234 | 99.98% | - | - | 14,191 | 0.02% | 70,178,425 |
Resolution 7 | 70,164,234 | 99.98% | - | - | 14,191 | 0.02% | 70,178,425 |
Resolution 8 | 70,164,234 | 99.98% | - | - | 14,191 | 0.02% | 70,178,425 |
Resolution 9 | 70,164,234 | 99.98% | - | - | 14,191 | 0.02% | 70,178,425 |
Resolution 10 | 70,164,234 | 99.98% | - | - | 14,191 | 0.02% | 70,178,425 |
Resolution 11 | 70,164,234 | 99.98% | - | - | 14,191 | 0.02% | 70,178,425 |
Resolution 12 | 70,163,734 | 99.98% | 500 | 0.001% | 14,191 | 0.02% | 70,178,425 |
As at 10.30am on 21 September 2015, the total number of ordinary shares of £0.002 each eligible to be voted at the Annual General Meeting was 97,484,855.
-Ends-
For more information, please contact:
John Burt (Chief Executive Officer)
Julian Smith (Chief Financial Officer)
Abzena plc
Tel: +44 1223 903498
Email: john.burt@abzena.com or julian.smith@abzena.com
Christopher Golden and Ivonne Cantu
Cenkos Securities (Nominated Adviser and Broker)
Tel: +44 20 7397 8900
Mark Swallow and David Dible
Citigate Dewe Rogerson (Corporate and Financial PR)
Tel: +44 20 7638 9571
Email: abzena@citigatedr.co.uk
About Abzena
Abzena provides proprietary technologies and complementary services in the UK and US to enable the development and manufacture of biopharmaceuticals.
The Group comprises Antitope, PolyTherics and PacificGMP, which between them have built a global customer base including the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.
Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.
PacificGMP provides contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies.
PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals.
Abzena has its main operations in Cambridge, UK and in San Diego, CA, USA. The shares of Abzena plc are quoted on the AIM segment of the London Stock Exchange under the symbol ABZA.
www.abzena.com
Abzena (ABZA)